Who are ARRY-403, glucokinase activator; oral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MK-6072, HMS5552, Placebo to MK-8527, GK567, AZD0585.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arry-403-glucokinase-activator-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ARRY-403, glucokinase activator; oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ARRY-403, glucokinase activator; oral (ARRY-403, glucokinase activator; oral) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucokinase activator. Area: Diabetes.

phase 1 Glucokinase activator Glucokinase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

ARRY-403, glucokinase activator; oral (ARRY-403, glucokinase activator; oral) — Array BioPharma. Glucokinase activator

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ARRY-403, glucokinase activator; oral TARGET	ARRY-403, glucokinase activator; oral	Array BioPharma	phase 1	Glucokinase activator	Glucokinase
MK-6072	MK-6072	Merck Sharp & Dohme LLC	phase 3	Glucokinase activator	Glucokinase (GCK)
HMS5552	HMS5552	Hua Medicine Limited	phase 3	Glucokinase activator	Glucokinase (GCK)
Placebo to MK-8527	Placebo to MK-8527	Merck Sharp & Dohme LLC	phase 3	Glucokinase activator	Glucokinase (GCK)
GK567	GK567	Galderma R&D	phase 3	Glucokinase activator	Glucokinase (GCK)
AZD0585	AZD0585	AstraZeneca	phase 3	Glucokinase activator	Glucokinase (GCK)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucokinase activator class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Array BioPharma · 1 drug in this class
AstraZeneca · 1 drug in this class
Galderma R&D · 1 drug in this class
Hua Medicine Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARRY-403, glucokinase activator; oral — Competitive Intelligence Brief. https://druglandscape.com/ci/arry-403-glucokinase-activator-oral. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab